126 related articles for article (PubMed ID: 2166720)
1. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer.
Ettinger DS; Finkelstein DM; Abeloff MD; Chang YC; Smith TJ; Oken MM; Ruckdeschel JC
Invest New Drugs; 1990 May; 8(2):183-5. PubMed ID: 2166720
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study.
Ettinger DS; Finkelstein DM; Donehower RC; Chang AY; Green M; Blum R; Hahn RG; Ruckdeschel JC
Med Pediatr Oncol; 1989; 17(3):197-201. PubMed ID: 2546026
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.
Lad TE; Blough RR; Evrard M; Shevrin DP; Cobleigh MA; Johnson CM; Hange P
Invest New Drugs; 1989 Jul; 7(2-3):223-4. PubMed ID: 2551841
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of spirogermanium in patients with advanced colorectal carcinoma.
Ajani JA; Faintuch JS; McClure RK; Levin B; Boman BM; Krakoff IH
Invest New Drugs; 1986; 4(4):383-5. PubMed ID: 3583645
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of spirogermanium in advanced large bowel cancer. An Eastern Cooperative Oncology Group study.
Pandya KJ; Kramar A; Asbury RF; Haller DG
Am J Clin Oncol; 1988 Aug; 11(4):496-8. PubMed ID: 3407630
[TBL] [Abstract][Full Text] [Related]
6. [Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
Bui NB; Chauvergne J; Brunet R; Richaud P; Hoerni B; Lagarde C; Le Guillou M
Bull Cancer; 1986; 73(1):65-7. PubMed ID: 3779124
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of oral spirogermanium.
Harvey J; McFadden M; Smith FP; Joubert L; Schein PS
Invest New Drugs; 1990 Feb; 8(1):53-6. PubMed ID: 2345069
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of spirogermanium and vindesine in malignant glioma.
Alavi JB; Schoenfeld D; Skeel RT; Kirkwood R; Tsung L; Marsh JC
Am J Clin Oncol; 1989 Feb; 12(1):8-10. PubMed ID: 2912024
[TBL] [Abstract][Full Text] [Related]
9. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Asbury RF; Cnaan A; Johnson L; Harris J; Zaentz SD; Haller DG
Am J Clin Oncol; 1994 Apr; 17(2):166-9. PubMed ID: 8141110
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of spirogermanium in patients with advanced malignant lymphoma.
Sessa C; ten Bokkel Huinik W; Clavel M; Lev LM; Joss RA; Renard J; Cavalli F
Invest New Drugs; 1989 Jul; 7(2-3):219-22. PubMed ID: 2793376
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of spirogermanium in advanced (extensive) non-small cell lung cancer.
Dhingra HM; Umsawasdi T; Chiuten DF; Murphy WK; Holoye PY; Spitzer G; Valdivieso M
Cancer Treat Rep; 1986 May; 70(5):673-4. PubMed ID: 3708617
[No Abstract] [Full Text] [Related]
12. Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary.
Weiselberg L; Budman DR; Schulman P; Vinciguerra V; Degnan TJ; Pasmantier M
Cancer Treat Rep; 1982 Aug; 66(8):1675-6. PubMed ID: 7201885
[No Abstract] [Full Text] [Related]
13. A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials Group Study.
Eisenhauer E; Kerr I; Bodurtha A; Iscoe N; McCulloch P; Pritchard K; Quirt I
Invest New Drugs; 1985; 3(3):303-5. PubMed ID: 4066224
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
Eisenhauer E; Quirt I; Connors JM; Maroun J; Skillings J
Invest New Drugs; 1985; 3(3):307-10. PubMed ID: 4066225
[TBL] [Abstract][Full Text] [Related]
15. Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
Boros L; Tsiatis AA; Neiman RS; Mann RB; Glick JH
Cancer Treat Rep; 1986 Jul; 70(7):917-8. PubMed ID: 3719586
[No Abstract] [Full Text] [Related]
16. Phase II study of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group Study.
Saiers JH; Blumenstein B; Slavik M; Costanzi JH; Crawford ED
Cancer Treat Rep; 1987 Dec; 71(12):1305-6. PubMed ID: 3690546
[No Abstract] [Full Text] [Related]
17. Phase II trial of N-methylformamide in advanced head and neck cancer.
Vogel WC; Forastiere AA; Natale RB; Takasugi BJ; Schnur G
Invest New Drugs; 1987; 5(2):203-6. PubMed ID: 3654153
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of spirogermanium in malignant melanoma: a Southwest Oncology Group Study.
Goodwin JW; Kopecky K; Slavik M; Tranum BL; Balcerzak SP; Fletcher WS; Costanzi JJ
Cancer Treat Rep; 1987 Oct; 71(10):985-6. PubMed ID: 3652061
[No Abstract] [Full Text] [Related]
19. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase II trial.
Kavanagh JJ; Saul PB; Copeland LJ; Gershenson DM; Krakoff IH
Cancer Treat Rep; 1985 Jan; 69(1):139-40. PubMed ID: 3967257
[No Abstract] [Full Text] [Related]
20. Phase II trial of spirogermanium for treatment of advanced breast cancer.
Falkson G; Falkson HC
Cancer Treat Rep; 1983 Feb; 67(2):189-90. PubMed ID: 6825129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
